- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PD-L1 negative
- PR positive
- ER negative
- PR negative
- EGFR negative
- BRAF positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Adjuvant Therapy (except reconstruction)
- Anthracycline
- Anti-HER2 Therapy
- Anti-PD-1/PD-L1 Based Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Endocrine Therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
1571 trials
Trials Without a Placebo
Knoxville, TN (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether ziltivekimab can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and inflammation. Participants will inject the medicine regularly. The study aims to see if reducing inflammation can help prevent serious heart problems.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<50 mi)
Waitlist
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trialstudies if a cholesterol-lowering medication can reduce heart attack, stroke and death in people hospitalized for a heart attack.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
Knoxville, TN (<50 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing etrasimod, a medication aimed at treating severe ulcerative colitis in adolescents aged 12 to 17. The drug works by calming the immune system to reduce inflammation in the colon. Participants will be treated for up to a year, with an option to continue for several more years. Etrasimod is an oral medication designed to help with inflammatory conditions.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Recruiting
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is designed to study the safety and effectiveness of a new stent for people with carotid artery stenosis.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Recruiting
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new device called the AccuCinch Ventricular Restoration System in patients with a specific type of heart failure. The device helps the heart pump blood more effectively by supporting and reshaping its lower chamber. The study aims to see if this device, combined with standard medical treatment, is safe and effective. The CorCap Cardiac Support Device (CSD) is a predecessor that has shown safety and effectiveness in improving left ventricular structure and function in heart failure patients.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will compare two methods of preventing stroke in patients with asymptomatic high-grade carotid stenosis. One group will have endarterectomy and the other will have carotid stenting with embolic protection.
Efficacy & Safety Awards
No Placebo-Only Group
Tennova Healthcare/ Turkey Creek Medical Center
TreatmentsIntensive Medical Management - no CEA (Other)Intensive Medical Management - no CAS (Other)Carotid Stenting (CAS) (Device)Carotid endarterectomy (CEA) (Procedure)
Sponsors and Investigators
Brajesh K. Lal, MD, George Howard, DrPH, Lloyd Edwards, PhD, James F. Meschia, MD
Knoxville, TN (<50 mi)
Recruiting
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the safety and feasibility of a new device called the Viper Catheter System, which is designed to remove blood clots from the lungs of patients with serious but not fully blocking clots. The device works by being inserted into the blood vessels and physically extracting the clots to help restore normal blood flow.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new type of stent that releases a drug to keep heart arteries open in patients with certain types of heart disease. The goal is to see if it works as well as current treatments. Drug-eluting stents, which release drugs to prevent artery blockage, have shown promising results and are a major focus in cardiovascular medicine.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Heart Failure trials are postedWe'll send you an email whenever new trials are posted
Knoxville, TN (<50 mi)
Waitlist
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a device called the Cordella PA Sensor System, which monitors heart pressure. It is aimed at patients with moderate to severe heart failure who need better treatment options. The device helps doctors track heart function and adjust treatments accordingly. The Cordella PA Sensor System is a novel device for continuous monitoring of heart pressure, similar to the previously approved CardioMEMS device.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a new combination of cancer treatments for bladder cancer patients who can't use standard chemotherapy. It uses drugs that help the immune system fight cancer and a drug that targets and kills cancer cells directly.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<50 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares proton beam radiation therapy with intensity modulated photon radiotherapy in treating patients with esophageal cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<50 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Throat Cancer trials are postedWe'll send you an email whenever new trials are posted
Knoxville, TN (<50 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing standard therapy (chemotherapy plus cetuximab) to adding bevacizumab to standard chemotherapy, versus a combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent).
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<50 mi)
Waitlist
Phase 1 & 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing 3 medicines to treat relapsed/refractory DLBCL, a type of NHL cancer, to see if they're safe & effective. Participants will receive them through IV infusion & taking a pill.
Efficacy & Safety Awards
No Placebo-Only Group
1
2
3
…50